Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases

被引：1
|
作者：
Lai-Tiong, F. [1 ]
机构：
[1] Gard Canc Inst, Oncol Unit, Rue Prof Henri Pujol, F-30900 Nimes, France
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2018年 / 39卷 / 05期
关键词：
Pertuzumab; Her2-positive breast cancer; Metastases; Complete response;
D O I：
10.12892/ejgo4026.2018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Her2-positive breast cancers represent about 20 percent of breast cancer patients. Her2-positive breast cancers have more aggressive and poorer prognosis. However, with the emergence of new therapies, outcomes have changed with improvement in survival. Pertuzumab is a new drug, a monoclonal antibody against Her2, available for use in the treatment of Her2-positive breast cancer.
引用
收藏
页码：845 / 846
页数：2
相关论文
共 50 条
  • [21] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    CANCER RESEARCH, 2013, 73
  • [22] Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
    Tian, Tian
    Ye, Jing
    Zhou, Sihai
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 720 - 727
  • [23] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [24] The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
    Liem, Jean A.
    Kurniawan, Andree
    Christiano, Joysya
    Argo, Teresa M.
    Law, Natasha K.
    Asafia, Darlene
    ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [25] Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab
    Conte, B.
    Fabi, A.
    Poggio, F.
    Blondeaux, E.
    Dellepiane, C.
    D'Alonzo, A.
    Staiano, A.
    Buono, G.
    Arpino, G.
    Magri, V.
    Naso, G.
    Presti, D.
    Mura, S.
    Fontana, A.
    Cognetti, F.
    Molinelli, C.
    Pastorino, S.
    Bighin, C.
    Lambertini, M.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [27] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [28] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [29] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    PharmacoEconomics, 2015, 33 : 13 - 23
  • [30] Trastuzumab/Pertuzumab plus Radiochemotherapy for HER2-positive AEG Tumor
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (06): : 520 - +
12345